InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,321.41
(
0.25%
)
US TECH 100
18,243.60
(
0.26%
)
Dow Jones
39,872.99
(
0.17%
)
Brent Oil
82.19
(
-0.32%
)
Bitcoin
69,966.06
(
-0.24%
)
Post# of 459547
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Mikesc

Send PM Follow Ignore
Followers 23
Posts 2120
Boards Moderated 0
Alias Born 06/21/2015

Mikesc

Re: None

Wednesday, 05/29/2019 1:55:25 PM

Wednesday, May 29, 2019 1:55:25 PM

Post# of 459547
This could be Anavex 273.


The FDA grants priority review to medicines that have the potential to provide significant improvements in the treatment of a serious disease, and the designation shortens the review period to six months from the standard 10 months. The agency set a target action date of Sept. 28 for the Vascepa sNDA.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent AVXL News
More AVXL News
InvestorsHub NewsWire

"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM

North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM

Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM

Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM

VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM

ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM

Start posting your company's news
Only $200 per official company press release!